← FDA DRUG APPROVALS

FDA ANDA · ANDA212947

MEMANTINE HYDROCHLORIDE

Sponsor: YILING

APPLICATION
ANDA212947
TYPE
ANDA
ORIGINAL APPROVAL
2020-04-03
LATEST ACTION
2024-05-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

MEMANTINE HYDROCHLORIDEPrescription
MEMANTINE HYDROCHLORIDE 5MG · TABLET · ORAL
MEMANTINE HYDROCHLORIDEPrescription
MEMANTINE HYDROCHLORIDE 10MG · TABLET · ORAL

Approval history

2024-05-17Manufacturing (CMC) · Supplement 1 · unknownAP
2020-04-03UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →